Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cronos GroupFRA:7CI +0.33%85 Debt-to-EBITDA is 0.14 as of Mar. 2026. GuruFocus rates FRA:7CI with a GF Score™ of 85/100 and a GF Value™ of €3.04 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 692 Drug Manufacturers companies, Cronos Group ranks worse than 144508.53% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Cronos Group's Debt-to-EBITDA or its related term are showing as below:
FRA:7CI'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.5 Med: -0.05 Max: 0.01
Current: -0.56
During the past 12 years, the highest Debt-to-EBITDA Ratio of Cronos Group was 0.01. The lowest was -3.50. And the median was -0.05.
FRA:7CI's Debt-to-EBITDA is ranked worse than 100% of 692
companies
in the Drug Manufacturers industry
Industry Median: 1.68
vs FRA:7CI: -0.56
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Cronos Group Debt-to-EBITDA Related Terms
Cronos Group Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Cronos Group's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cronos Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cronos Group Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cronos Group's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cronos Group's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Cronos Group (FRA:7CI) has a Debt-to-EBITDA of 0.14 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Cronos Group. According to the industry distribution chart, Cronos Group ranks #999999 out of 692 companies in the Drug Manufacturers industry.
Is Cronos Group's Debt-to-EBITDA too high?
Cronos Group's current Debt-to-EBITDA is 0.14. The Drug Manufacturers industry median Debt-to-EBITDA is 1.68. Cronos Group's value of 0.14 is 91.7% below this industry median. Based on the distribution chart, Cronos Group ranks #999999 out of 692 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cronos Group has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cronos Group's Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cronos Group ranks #999999 out of 692 companies for Debt-to-EBITDA. This places Cronos Group in the lower half of its industry. The industry median Debt-to-EBITDA is 1.68. Cronos Group's value of 0.14 is 91.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.68, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cronos Group's current Debt-to-EBITDA of 0.14 is 91.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Cronos Group. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cronos Group's current Debt-to-EBITDA is 0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cronos Group stock overvalued right now?
Based on GuruFocus' analysis, Cronos Group (FRA:7CI) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.04, compared to a current price of €2.47 — trading 18.9% below its estimated fair value. The current Debt-to-EBITDA is 0.14 and 91.7% below the Drug Manufacturers industry median of 1.68. Cronos Group's overall GF Score™ is 85/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Cronos Group (FRA:7CI), the current Debt-to-EBITDA is 0.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cronos Group (FRA:7CI) Overvalued in 2026?
Based on GuruFocus' analysis, Cronos Group stock appears to be undervalued.
The current stock price of €2.47 is trading 18.9% below its estimated GF Value™ of €3.04.
GuruFocus considers Cronos Group to be Modestly Undervalued.
Key valuation signals for FRA:7CI:
Debt-to-EBITDA: 0.14
GF Value™: €3.04 vs. price of €2.47 (18.9% below fair value)
Industry Position: 91.7% below the Drug Manufacturers median (#999999 of 692)
No single metric tells the full story. See the FRA:7CI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cronos Group Inc is a cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology, and product development. With a passion for responsibly elevating the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach, PEACE NATURALS, LIT, and Lord Jones. The company operates in Canada, Israel, and other countries, with the majority of its revenue generated from Canada.
85GF Score
Get the complete analysis for FRA:7CI
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7CI has been successfully added to your 
